Tumor Biology

, Volume 35, Issue 9, pp 8659–8664 | Cite as

PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration

  • Huan-yong Che
  • Hang-yuan Guo
  • Xu-wei Si
  • Qiao-ying You
  • Wei-ying Lou
Research Article


The tyrosine and phosphoinositide kinases play crucial roles in the regulation of many cancer cell processes including cell survival and cell motility. Anaplastic thyroid carcinoma (ATC) is a rare and deadly type of thyroid cancer, and so far, there are no effective therapeutic compounds for ATC. Herein, we investigate the anticancer activities of PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, in ATC therapy. We found that PP121 is effective at suppressing cell viability, inducing cell apoptosis, and inhibiting cell migration and invasion. The potential anticancer mechanism for PP121 might be its inhibitory effects on phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways in ATC cells. Furthermore, PP121 is effective at suppressing ATC tumor growth in vivo. In summary, our studies suggest that PP121 might be a promising therapeutic compound for ATC treatment, which might shed new light on ATC therapy.


Anaplastic thyroid carcinoma PP121 Tyrosine Phosphoinositide kinase Proliferation Migration 


Conflicts of interest



  1. 1.
    Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13(4):453–64.CrossRefPubMedGoogle Scholar
  2. 2.
    Sun C, Xu X, Wang X, et al. Thymic carcinoma with tumor thrombus protruding into the superior vena cava and the right atrium. Thoracic Cancer. 2013;4(3):333–4.Google Scholar
  3. 3.
    Zhang J, Wang H, Tian W, et al. Brown tumor of the rib as a first presentation of primary hyperparathyroidism: report of three cases and literature review. Thoracic Cancer. 2013;4(4):474–8.Google Scholar
  4. 4.
    Wiseman SM, Masoudi H, Niblock P, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol. 2007;14(2):719–29.CrossRefPubMedGoogle Scholar
  5. 5.
    Bruni P, Boccia A, Baldassarre G, et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1. Oncogene. 2000;19(28):3146–55.CrossRefPubMedGoogle Scholar
  6. 6.
    Weng LP, Gimm O, Kum JB, et al. Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum Mol Genet. 2001;10(3):251–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997;57(21):4710–3.PubMedGoogle Scholar
  8. 8.
    Gimm O, Perren A, Weng LP, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue and benign and malignant epithelial thyroid tumors. Am J Pathol. 2000;156(5):1693–700.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Ringel MD, Hayre N, Saito J, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 2001;61(16):6105–11.PubMedGoogle Scholar
  10. 10.
    García-Rostán G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65(22):10199–207.CrossRefPubMedGoogle Scholar
  11. 11.
    Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20(9):975–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhang J, Wang P, Dykstra M, et al. Platelet-derived growth factor receptor-α promotes lymphatic metastases in papillary thyroid cancer. J Pathol. 2012;228(2):241–50.CrossRefPubMedGoogle Scholar
  13. 13.
    Kim MJ, Kim SK, Park HJ, et al. PDGFRA promoter polymorphisms are associated with the risk of papillary thyroid cancer. Mol Med Rep. 2012;5(5):1267–70.PubMedGoogle Scholar
  14. 14.
    Malkomes P, Oppermann E, Bechstein WO, et al. Significantly high expression of platelet-derived growth factor (PDGF) in benign nodules of the thyroid: relevance in the development of goitre recurrence? Langenbecks Arch Surg. 2011;396(8):1165–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Chen KT, Lin JD, Liou MJ, et al. An aberrant autocrine activation of the platelet-derived growth factor alpha-receptor in follicular and papillary thyroid carcinoma cell lines. Cancer Lett. 2006;231(2):192–205.CrossRefPubMedGoogle Scholar
  16. 16.
    Apsel B, Blair JA, Gonzalez B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008;4(11):691–9.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.CrossRefPubMedGoogle Scholar
  18. 18.
    Cantley LC. The phosphoinositide 3-kinase pathway. Science (New York, NY). 2002;296(5573):1655–7.CrossRefGoogle Scholar
  19. 19.
    Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004;9(6):667–76.CrossRefPubMedGoogle Scholar
  20. 20.
    Oka N et al. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res. 2005;65(17):7546–53.PubMedGoogle Scholar
  21. 21.
    Moses SA et al. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res. 2009;69(12):5073–81.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Kundra V, Escobedo JA, Kazlauskas A, et al. Regulation of chemotaxis by the platelet-derived growth factor receptor-beta. Nature. 1994;367(6462):474–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956–67.CrossRefPubMedGoogle Scholar
  24. 24.
    Engelman JA et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–43.CrossRefPubMedGoogle Scholar
  25. 25.
    Sergina NV et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437–41.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Huan-yong Che
    • 1
  • Hang-yuan Guo
    • 1
  • Xu-wei Si
    • 1
  • Qiao-ying You
    • 1
  • Wei-ying Lou
    • 1
  1. 1.Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang UniversityShaoxingPeople’s Republic of China

Personalised recommendations